Korean stem cell deal nets ACT $2M in fees
Advanced Cell Technology Inc. has formed a licensing agreement with Korean stem cell company CHA Bio & Diostech Co. Ltd., which could bring in up to $1.9 million in milestone payments.
[Read the full article here]Related News:
ACT gains exclusive license for blood-related stem cell tech
Cephalon in Stem Cell Deal
St. Luke's, Korean university ink deal on stem cell research